Chemotherapy in gallbladder cancinoma;Chimiothérapie dans le cancer de la vésicule biliaire

Presse Medicale

Volumn 39, Issue 12, 2010, Pages 1238-1245

  Abahssain, Halima ^a   Afchain, Pauline ^b   Melas, Nawfal ^a   Ismaili, Nabil ^a   Rahali, Rabia ^a   Rabti, Hind M ^a   Errihani, Hassan ^a  

^a MOHAMMED V UNIVERSITY   (Morocco)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DRUG RESPONSE; GALLBLADDER CARCINOMA; HUMAN; QUALITY OF LIFE; SHORT SURVEY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; CISPLATIN; DEOXYCYTIDINE; FLUOROURACIL; GALLBLADDER NEOPLASMS; HUMANS; LEUCOVORIN; MITOMYCIN; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78649806812     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2010.09.002     Document Type: Short Survey

References (41)

1. Misra S., Chaturvedi A., Misra N.C., Sharma I.D. Carcinoma of the gallbladder. Lancet Oncol 2003, 4:167-176.
2. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J Clin 1998, 48:6-29.
3. Randi G., Franceschi S., La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006, 118:1591-1602.
4. Chaurasia P., ThakurMK ShuklaH.S. What causes cancer gallbladder?: a review. HPB Surg 1999, 11:217-224.
5. Serra I., Diehl A.K. Number and size of stones in patients with asymptomatic and symptomatic gallstones and gallbladder carcinoma. J Gastrointest Surg 2002, 6:272-273.
6. De Groen P.C., Gores G.J., LaRusso N.F., Gunderson L.L., Nagorney DM Biliary tract cancers. N Engl J Med 1999, 341:1368-1378.
7. Mahe M., Stampfli C., Romestang P., Salerno N., Gerard J.P. Primary carcinoma of the gallbladder: potential for external radiation therapy. Radiother Oncol 1994, 33:204-208.
8. Gallardo J., Rubio B., Villanueva L., Barajas O. Gallbladder cancer, a different disease that needs individual trials. J Clin Oncol 2005, 23:7753-7754. [author reply 7754-5].
9. Valle J.W., Wasan H.S., Palmer D.D., Cunningham D., Anthoney D.A., Maraveyas A., et al. Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol 2009, 27:4503.
10. Glimelius B., Hoffman K., Sjoden P.O., Jacobsson G., Sellström H., Enander L.K., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996, 7:593-600.
11. Dwary A.D., Sharma A., Mohanti B.K., Pal S., Garg P., Raina V., et al. A randomized controlled trial (RCT) comparing best supportive care (BSC), 5-FU plus folinic acid (FUFA) and, gemcitabine plus oxaliplatin (Gem-Ox) in management of unresectable gallbladder cancer (GBC). JCO 2009, 27:4521.
12. Eckel F., Schmid R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007, 96:896-902.
13. Yonemoto N., Furuse J., Okusaka T., Yamao K., Funakoshi A., Ohkawa S., et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007, 37:843-851.
14. Knox J.J., Hedley D., Oza A., Feld R., Siu L.L., Chen E., et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005, 23:2332-2338.
15. Gallardo J.O., Rubio B., Fodor M., Orlandi L., Yáñez M., Gamargo C., et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001, 12:1403-1406.
16. Reyes-Vidal J., Gallardo J., Yáñez E. Gemcitabine: gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic gallbladder cancer: results of the phase II GOCCHI study 2000-13 [abstract 1095]. Proc Am Soc Clin Oncol 2003, 22:273.
17. Doval D.C., Sekhon J.S., Gupta S.K., Fuloria J., Shukla V.K., Gupta S., et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004, 90:1516-1520.
18. Ducreux M., Van Cutsem E., Van Laethem J.L., Gress T.M., Jeziorski K., Rougier P., et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer 2005, 41:398-403.
19. Kornek G.V., Schuell B., Laengle F., Gruenberger T., Penz M., Karall K., et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 2004, 15:478-483.
20. Rao S., Cunningham D., Hawkins R.E., Hill M.E., Smith D., Daniel F., Ross P.J., et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005, 92:1650-1654.
21. Takada T., Amano H., Yasuda H., Nimura Y., Matsushiro T., Kato H., et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002, 95:1685-1695.
22. Kresl J.J., Schild S.E., Henning G.T., Gunderson L.L., Donohue J., Pitot H., et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys 2002, 52:167-175.
23. Czito B.G., Hurwitz H.I., Clough R.W., Tyler D.S., Morse M.A., Clary B.M., et al. Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys 2005, 62:1030-1034.
24. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E., et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19:3159-3167.
25. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
26. Nonomura A., Ohta G., Nakanuma Y., Izumi R., Mizukami Y., Matsubara F., et al. Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method. Liver 1988, 8:157-166.
27. Lee C.S., Pirdas A. Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours. Pathol Res Pract 1995, 191:1087-1091.
28. Ito Y., Takeda T., Sasaki Y., Yamada T., Ishiguro S., Imaoka S., et al. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract 2001, 197:95-100.
29. Nakazawa K., Dobashi Y., Suzuki S., Fujii H., Takeda Y., Ooi A., et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 2005, 206:356-365.
30. Werneburg N.W., Yoon J.H., Higuchi H., Gores G.J. Bile acids activate EGF receptor via a TGF-alphadependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol 2003, 285. [G31-6].
31. Philip P.A., Mahoney M.R., Allmer C., Thomas J., Pitot H.C., Kim G., et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006, 24:3069-3074.
32. Ramanathan R.K., Belani C.P., Singh D.A., Tanaka M., Lenz H.J., Yen Y., Kindler H.L., et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009, 64:777-783.
33. Malka D., Trarbach T., Fartoux L., Mendiboure J., de la Fouchardière C., Viret F., et al. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial. J Clin Oncol 2009, 27:4520.
34. Hida Y., Morita T., Fujita M., Miyasaka Y., Horita S., Fujioka Y., et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res 1999, 19:2257-2260.
35. Zhu A.X., Meyerhardt J.A., Blaszkowsky L.S., Kambadakone A.R., Muzikansky A., Zheng H., et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010, 11:48-54.
36. Takimoto C.H., Awada A. Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008, 61:535-548.
37. Yamaguchi K., Nakano K., Nagai E., Chijiiwa K., Kinoshita M., Ohta M., et al. Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma. Hepatogastroenterology 2005, 52:713-718.
38. Saetta A.A. K-ras, p53 mutations, and microsatellite instability (MSI) in gallbladder cancer. J Surg Oncol 2006, 93:644-649.
39. Saetta A.A., Papanastasiou P., Michalopoulos N.V., Gigelou F., Korkolopoulou P., Bei T., et al. Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch 2004, 445:179-182.
40. Tannapfel A., Sommerer F., Benicke M., Katalinic A., Uhlmann D., Witzigmann H., et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003, 52:706-712.
41. El-Khoueiry A.B., Rankin C., Lenz H.J. A phase II study of Sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. Proc Am Soc Clin Oncol 2007, 25:4639.